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Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder that impairs memory and cognition. One
of the major neuropathological hallmarks is the accumulation of the extracellular senile plaques that
are mainly composed of amyloid beta (Aβ) protein. Plaques are associated with synapse loss,
dystrophic neurites and altered neurite trajectories. A reversal of such morphological changes has
been observed days after single dose anti Aβ immunotherapy. In this study we investigated the
extended effects of a single dose of passive anti Aβ immunotherapy on morphological changes
associated with senile plaques. We found that although plaque burden was not reduced 30 days after
immunotherapy, there were fewer dystrophic neurites around each plaque, a recovery of synapse
density, and normalization of neurite curvature near plaques. Taken together these results suggest
that single dose immunotherapy is sufficient to cause lasting benefits to the morphology of cortical
neurons, implying substantial plasticity of neural circuits despite the continued presence of plaques.
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1. Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder affecting more than 4 million
Americans and >30 million individuals worldwide (Kawas, et al., 2003). It results in memory
loss, personality changes and cognitive decline. The main neuropathological hallmarks of AD
are intracellular neurofibrillary tangles consisting of hyperphosphorylated tau and extracellular
senile plaque deposition consisting mainly of amyloid beta (Aβ) peptide. Plaques have been
shown to disrupt synaptic integration in mice (Stern, et al., 2004) hence possibly affecting
cognition. In addition, plaques are also associated with altered neuritic trajectories, dystrophic
neurites and dendritic spine loss (D’Amore, et al., 2003, Knowles, et al., 1998, Knowles, et al.,
1999, Spires, et al., 2005, Tsai, et al., 2004). Neurites have been shown to be more curved
inside and close to plaques compared to plaques and that has been suggested to interrupt
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neuronal networks (Knowles, et al., 1999, Le, et al., 2001). Swollen dystrophic neurites appear
around plaques in AD and are may interfere with cell transport (Spires and Hyman, 2004).
Work in several mouse models has shown that dendritic spine loss is most profound around
plaques (Moolman, et al., 2004, Spires, et al., 2005, Spires-Jones, et al., 2007). The cause for
this spine loss could be the concentration of toxic oligomeric Aβ species (or other toxic
molecules) around plaques (Koffie, et al., 2009, Meyer-Luehmann, et al., 2008, Shankar, et
al., 2008).
Removing Aβ plaques and oligomeric species could prove to be a valuable treatment (Schenk,
et al., 1999). So far it has been shown that with passive immunotherapy it is possible to remove
Aβ plaques in mice (Bacskai, et al., 2001, Bard, et al., 2000, Lombardo, et al., 2003, Morgan,
et al., 2000). Along with clearing plaques, immunotherapy restores neurite architecture,
increases synapse density and improves behavior (Dodart, et al., 2002, Kotilinek, et al.,
2002, Lombardo, et al., 2003, Wilcock, et al., 2006, Thakker, et al., 2009). These events have
been shown to occur over several days. Indeed, early improvements in neuritic morphology
occur even prior to amyoloid clearance, within 24 hours (Brendza, et al., 2005, Spires-Jones,
et al., 2008). However, no extended effects of plaque associated neuritic changes have yet been
investigated. It is essential to observe how long the recovery of neuritic morphological changes
after a single dose of anti Aβ treatment persists. In this study we performed a single dose passive
immunotherapy and quantified morphological changes 30 days later. We hypothesize that
single-dose immunotherapy can have lasting beneficial effects on plaque-associated
anatomical degeneration.
2. Results
After acute anti Aβ immunotherapy treatment it has been shown that Aβ plaques have been
cleared within a few days (Bacskai, et al., 2001). To determine whether Aβ plaques are present
30 days after a single dose of anti-Aβ antibody treatment, we labeled plaques with R1282
immunostaining and calculated the plaque burden in treated and untreated areas of cortex. We
found that plaques were present in Tg2576 cortex but not non-transgenic controls as expected.
Treatment with anti-Aβ antibody 3D6 did not lead to a statistically significant reduction in
plaques observed 30 days post-treatment (Fig 1). Plaque burden was not significantly reduced
in anti-Aβ treated mice (mean plaque burden = 0.99% ± 0.99 in region treated with antibody)
either in comparison to animals treated with an irrelevant antibody (mean plaque
burden=1.42% ± 1.54 in treated area) or when compared to a region within the anti-Aβ treated
brain that was not exposed to antibody treatment (mean plaque burden in untreated area of anti-
Aβ treated mice=1.01% ± 1.06 (p>0.05)). These data indicate that despite early clearance of
plaques with passive immunotherapy as has been observed previously, there is a probable re-
deposition within 30 days after a single dose of monoclonal antibody in this model.
Dystrophic neurites are often seen around plaques in AD and are an indication of
neurodegeneration (Spires and Hyman, 2004). A reduction in the number of dystrophies has
been observed in the first several days after anti Aβ immunotherapy treatment (Brendza, et al.,
2005). We wanted to investigate whether the effect would persist 30 days after a single dose
of passive immunotherapy treatment. In the antibody treated area there was a reduction in the
number of axonal dystrophies per plaque in mice treated with anti Aβ (3D6) antibody (mean
number of dystrophies per plaque=2.85 ± 0.64), compared to the control anti human tau
antibody (mean number of dystrophies per plaque=4.51 ± 1.75, t-test p<0.001) (Fig 2). The
effect was only seen in the area treated with anti Aβ antibody. There was a reduction in axonal
dystrophies when anti Aβ treated cortex was compared to the area of cortex untreated with
antibody in the same animals (p<0.01). No such effect was seen in Tg2576 animals treated
with control antibody. These results together with previous findings suggest that dystrophic
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swellings can be rapidly reversed and the recovery can persist for at least 30 days despite the
presence of Aβ plaques with a single dose of anti Aβ treatment.
Synapse loss is the strongest correlate of cognitive decline in Alzheimer’s disease (Terry, et
al., 1991). We wanted to determine whether improvements in synapse density with a single
dose of anti Aβ immunotherapy treatment persisted for an extended period (30 days). Untreated
Tg2576 cortex had a trend toward synapse loss compared to controls (Mann-Whitney test
p=0.05) of 55% loss in synaptophysin immunoreactivity. We detected a significant 56%
increase of presynaptic terminal (synaptophysin) optical density in Tg2576 cortex treated with
anti Aβ antibody compared to the control treatment, so that synaptophysin optical density in
the treated area is the same as in non-tg animals (p<0.01 Mann-Whitney test, Fig 3). In non-
Tg animals, treatment with anti Aβ antibody had no effect compared to treatment with control
antibody. These results suggest that synapse loss can be rescued by single dose passive
immunotherapy and persist 30 days after the treatment despite the presence of fibrillar Aβ.
It has been shown that neurites have altered trajectories around plaques in AD (D’Amore, et
al., 2003, Knowles, et al., 1998, Knowles, et al., 1999, Le, et al., 2001, Lombardo, et al.,
2003) and with passive immunotherapy this can be rescued in several days (Lombardo, et al.,
2003). In Tg2576 cortex treated with the control antibody, axons have an average curvature
ratio of 1.026 ± 0.027. Anti-Aβ treated areas average curvature ratio was 1.034 ± 0.038 showing
no effect of treatment on average curvature when distance from a plaque was not taken into
account (t-test p>0.05). When phantom plaques were created and distance to axons measured
we found no difference between axons close (<50 μm) and far (>50 μm) from phantom plaques
as expected. We calculated the ratio of close to far and found it to be 1.0057 and used that as
a control baseline (Fig. 4). However, in transgenic animals treated with control antibody, axons
were more curved close (<50 μm) to plaques compared to far (>50 μm) from plaques (curvature
ratio 1.05 ± 0.065 and 1.034 ± 0.042, respectively, ratio close to far 1.011 t-test, p<0.05) (Fig.
4). 30 days after the treatment with anti-Aβ antibody there was no difference between axons
that were close (curvature ratio 1.056 ± 0.042) to those that were far (curvature ratio 1.045 ±
0.057 ratio close to far 1.007) from plaques (t-test, p>0.05) (Fig. 4), indicating some
normalization of axon trajectory with anti-Aβ treatment, although the curvature does not
approach control levels.
Together, these data show lasting morphological benefits of a single dose of passive anti-Aβ
immunotherapy.
3. Discussion
The amyloid hypothesis of AD suggests that the onset and progression of pathogenesis of AD
is influenced by the accumulation of Aβ in the brain (Hardy and Selkoe, 2002). However,
plaques have been shown to poorly correlate with the progression of the disease (Arriagada,
et al., 1992). A much better indicator of cognitive decline is synaptic density, neurofibrillary
tangles and dystrophic neurites around plaques (Ingelsson, et al., 2004, McKee, et al., 1991,
Terry, et al., 1991), indicating that prolonged recovery of these markers is possibly more
important than plaque removal which could theoretically release more synaptotoxic soluble
species of Aβ.
In our study we showed that plaques were present 30 days after a single treatment with anti-
Aβ antibody similar to findings by Oddo et al. in another mouse model of AD (Oddo, et al.,
2004). Since immunotherapy is a well established way of clearing plaques (Bacskai, et al.,
2001, Bard, et al., 2000, Schenk, et al., 1999), it is likely that in our mice, plaques were cleared
quickly, then re-emerged during the 30 days post-treatment as seen in the triple transgenic
model (Oddo, et al., 2004).
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We find that despite the persistent Aβ plaques 30 days after treatment, the density of presynaptic
markers was increased. This indicates that it is possible to reverse synapse loss - one of the
strongest correlates with cognitive decline. It has been recently shown that dendritic spine
plasticity can be improved after 1 hour of immunotherapy treatment (Spires-Jones, et al.,
2008) and here we have shown that similar effects in presynaptic markers can persist for at
least 30 days.
Another important correlate with stages of dementia and a pathological hallmark of AD are
dystrophic neuritic swellings (McKee, et al., 1991, Spires and Hyman, 2004). It has been shown
that dystrophic neurites can recover 3 days after an anti Aβ treatment (Brendza, et al., 2005).
In the current study we showed that axonal dystrophies around plaques remain reduced 30 days
after the treatment despite the presence of Aβ plaques. This suggests that the presence of
fibrillar aggregates of Aβ does not preclude the recovery of either synapses or axonal
dystrophies. These results taken together with previous results indicate that dystrophic
swellings can appear within a matter of days (Meyer-Luehmann, et al., 2008), clear with passive
immunotherapy within several days (Brendza, et al., 2005), and the current study suggests that
this recovery can persist for 30 days.
It has been reported that dendrites and axons are more curved close compared to far from Aβ
plaques (D’more, et al., 2003, Garcia-Alloza, et al., 2006, Knowles, et al., 1998, Knowles, et
al., 1999) and that dendrites (labeled with SMI32) can straighten within 4 days after treatment,
an effect which persists for 32days (Lombardo, et al., 2003, McKee, et al., 1991). In this study
we found that, similar to the results with dendrites, 30 days after treatment, the curvature of
axons near plaques was the same as those farther away, while in animals treated with an
irrelevant antibody, curvature was still more pronounced near plaques.
It can be inferred from our study that anti Aβ treatment is sufficient to induce the recovery of
synapses and neurite morphology persists for at least 30 days despite the presence of fibrillar
plaques at this time point. It is possible that toxic oligomeric species being produced in the
Tg2576 animals are being sequestered into new plaques after an initial clearance of both soluble
and fibrillar species explaining the lingering beneficial effects on neurite morphology. We
presume that once the pre-treatment equilibrium of fibrillar and soluble species is reached,
another dose anti Aβ antibody would be necessary to continue the beneficial effects. This could
prove beneficial in patient immunotherapy trials as only one dose passive immunotherapy
treatment could provide lasting recovery of neurite morphology and by extension neural system
integrity.
4. Experimental Procedures
Animals and Surgery
All animal work conformed to National Institutes of Health and institutional guidelines.
Tg2576 mice expressing human amyloid precursor protein with the AD-associated Swedish
mutation (Hsiao, et al., 1996) between ages 18 to 26 month and non-transgenic littermate
controls were used for this study. A craniotomy was performed as described previously
(Bacskai, et al., 2002, Klunk, et al., 2002, Lombardo, et al., 2003, Skoch, et al., 2004). After
dura resection animals were treated with topical application of (25 μL volume) of either anti
Aβ antibody (3D6) (1mg/mL concentration) (Elan Pharmaceuticals) or an irrelevant human
tau antibody (12E8 or 16B5) (1 mg/mL concentration) (Elan Pharmaceuticals). Following the
treatment, the craniotomy was sealed with an 8mm diameter glass coverslip and animals were
left to recover. 30 days post treatment animals were euthanized using an overdose of Avertin
(400mg/kg, i.p.). Brains were fixed using 4% Paraformaldehyde and 15% glycerol for
cryoprotection for 48h then one hemisphere was sectioned at 50 μm using freezing microtome
while the other was paraffin embedded and sectioned at 16 μm, both were sectioned coronally.
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Plaque burden
Every 15th section (selected on systematic random basis) from the paraffin-embedded
hemisphere was deparafinized and blocked in 5% Normal Goat Serum (NGS) for 1h. Sections
were then immunostained with Aβ antibody R1282 (1: 500 in 1 % NGS in Tris-buffered saline,
gift from Dr. D. Selkoe, Brigham and Women’s Hospital, Boston, MA) and Alexa488
(Invitrogen, Eugene, OR) was used as a secondary antibody (1:100 in 1 % NGS in Tris-buffered
saline, Invitrogen, Eugene, OR). Aβ fluorescent immunostaining was detected by scanning
stained sections in a scan array reader (Perkin Elmer, Downers Growe, IL) using a 488 laser
for excitation. Scanned images were analyzed using ImageJ software. Regions of interest were
outlined in the superficial 200 μm of cortex under the craniotomy (the area that was exposed
to antibody treatment) and in the superficial 200 μm of an untreated region (piriform cortex).
The total area occupied by plaques was divided by the total area of the cortex sampled to obtain
the percentage of cortex covered by Aβ immunoreactivity (plaque burden).
Axon curvature
Every 10th PFA fixed (free floating) section (first section selected on systematic random basis)
was permeabilized using 0.5% TritionX-100 in TBS for 20 minutes followed by 1h blocking
in 5% NGS. To visualize axons the tissue was incubated with a SMI 312 (1:1000 in 1 % NGS
in Tris-buffered saline, Covance Research Products, Inc., Berkely, CA) antibody that
recognizes pan axonal neurofilament and conveniently labels axons and axonal dystrophies
associated with plaques. A secondary antibody anti-mouse IgG conjugated to Cy3 dye (1:200
in 1 % NGS in Tris-buffered saline, Jackson ImmunoResearch, West Grove, PA) was used and
then sections were counterstained with Thioflavine-S (0.05% in 50% ethanol) (Sigma, St.
Louis, MO).
Images for axon analysis were taken on upright Olympus BX51 (Olympus, Denmark)
fluorescence microscope with a DP70 camera sampling 100% of the 200 um of the area treated
with the antibody. Only axons longer than 20 μm were chosen for analysis and their curvature
ratio was calculated in Image J by dividing the curvilinear length of the axon by the straight
line length of the process (D’more, et al., 2003, Garcia-Alloza, et al., 2006, Knowles, et al.,
1999, Lombardo, et al., 2003). Distance from the measured axon segment to the closest senile
plaque (if present) was measured at three points – from each end and the midpoint of the
segment and the average distance was taken from these three measurements. Axons that were
closer than 50 μm to the plaque were defined as being close to the plaque and others as far
from the plaque.
Dystrophies per plaque
Every 15th section (selected on systematic random basis) was immunolabled with SMI312
antibody as described above using Alexa488 (Invitrogen, Eugene, OR) to visualize axons and
dystrophies. Plaques were immunolabled using Amyloid beta antibody R1282 (gift from Dr.
D. Selkoe, Brigham and Women’s Hospital, Boston, MA) as described above and visualized
using Cy3 (Jackson ImmunoResearch, West Grove, PA). Smi312 positive dystrophies within
the plaque area that were larger than 2.5 μm2 were classified as dystrophic neurites and counted
for each plaque using an upright Olympus BX51 (Olympus, Denmark) fluorescence
microscope. The average number of dystrophies per plaque was calculated.
Synapse quantification
Every 15th paraffin section (selected on systematic random basis) was deparaffinized and
incubated in 1 mg/ml pepsin in 0.2N HCl for 10 min and blocked in 5% NGS for 1h. Sections
were immunolabled with presynaptic marker antibody Sy38 (1:10 in 1 % NGS in Tris-buffered
saline, Synaptic Systems) with an anti-mouse Alexa 546 secondary antibody (1:100 in 1 %
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NGS in Tris-buffered saline, Invitrogen, Eugene, OR) and plaques were labeled with R1282
and an anti-rabbit Alexa 488 secondary antibody as described earlier. Optical density of
fluorescent immunostaining was determined using a Scan Array Express (Perkin Elmer, Boston
MA). A 568nm laser was used to excite the fluorophore and scans of each section were acquired
at 3 focal planes. In Image J software (free from the NIH), the three images of each section
were projected into one composite. Regions of interest were outlined in the superficial 200
μm of cortex under the craniotomy (the area that was exposed to antibody treatment) and in
the superficial 200 μm of an untreated region (piriform cortex). Mean grayvalues for each
group were calculated.
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Fig 1.
Plaque burden 30 days after anti Aβ immunotherapy treatment. Tg2576 and age-matched non-
transgenic animals were treated with topical application of either anit-Aβ antibody or anti
human tau antibody. The area treated with antibody is outlined in red in panel (A) and is referred
to in text as the treated cortex. (B) Plaques were immunolabeled with R1282 primary antibody
and visualized with Alexa488. (C) There was no difference in cortical plaque burden between
animals treated with an anti Aβ antibody 3D6 and those treated with control antibody 12E8
(p<0.05). Control non-transgenic animals had no plaques as expected. Scale bar 50 μm. Data
presented as mean ± SD. Panel with the coronal section was modified from the high resolution
mouse brain atlas (http://www.hms.harvard.edu/research/brain/atlas.html).
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Fig 2.
Effects of passive immunotherapy on axonal dystrophies. (A) Plaque-associated axonal
dystrophies (arrows) were analyzed on sections stained with SMI312 (green) and R1282 to
label plaques (red). (B) Quantification shows that a single topical treatment with an antibody
to Aβ caused a reduction in the average number of dystrophic axonal swellings per plaque 30
days after the treatment (** p<0.001). The effect on axons was observed only in the area treated
with anti Aβ antibody and was not seen in the untreated area or in animals treated with irrelevant
anti human tau antibody (12E8). Scale bar 20 μm. Data presented as mean ± SD.
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Fig 3.
Presynaptic terminal density increases 30 days after a single dose of passive immunotherapy
treatment. (A) SY38 synaptophysin staining (green) shows presynaptic terminal loss in the
area of cortex occupied by R1282 labeled (red) plaques (arrows). (B) A box plot of
synaptophysin optical density data shows that there is a trend towards 55% presynaptic terminal
loss in animals treated with the control anti tau antibody compared to non-transgenic animals
(# Mann-Whitney test p=0.0527). Presynaptic terminal density recovered in tissue treated with
anti Aβ antibody (3D6) compared to tissue treated with anti tau antibody (* Mann-Whitney
test p<0.01). The recovery occurred despite persistent plaque pathology. Scale bar 50 μm.
Optical density data were not normally distributed thus are presented in box plots with median,
maxima, and minima shown.
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Fig 4.
Effects of single dose passive immunotherapy treatment on axon curvature ratios. (A) Axon
curvature ratios were measured on SMI312 labeled axons (red) in proximity to Thioflavin S
positive plaques (blue). (B) After single dose topical application of antibody to Aβ (3D6) axons
close (<50 μm) to plaque were as curved as axons far (>50 μm) from plaque (p>0.05), however
without reaching the level of non-transgenic animals. Axons of animals treated with anti tau
antibody were significantly more curved close to plaques compared to far from plaques (*
p<0.05). Control animals had significantly straighter axons compared to transgenic animals
(p<0.05). Scale bar 10 μm. Data presented as mean ± SD.
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